Excellent, magnificent, fantastic! All of these superlatives (and more) describe Eli Lilly's (NYSE: LLY) performance in recent years as it has delivered market-crushing returns and strong regulatory progress. Though the stock might peak eventually, we aren't there yet, as the pharmaceutical giant proved ...
motleyfoolusx:lly
The healthcare industry is a fantastic place to find passive income. Healthcare is recession-proof, and there's always a need for better technology and new treatments. The industry's top dogs have been in the game for decades and can generate wealth for patient shareholders who come along for the ride. ...
motleyfoolusx:abbvusx:llyusx:nvo
A company's track record for paying dividends is a good indicator of how versatile and adaptable the business is in dealing with changing economic conditions. That doesn't mean that the dividend will always be safe and that payouts will always continue, but it's an important factor that dividend investors ...
motleyfoolusx:kousx:llyusx:td
The pharmaceutical industry is currently experiencing something of a renaissance thanks to the rise of blockbuster medications called glucagon-like peptide-1 (GLP-1) agonists. Perhaps the most well-known GLP-1 drugs are diabetes medication Ozempic and obesity care treatment Wegovy. Danish pharmaceutical ...
motleyfoolusx:lly
Eli Lilly (NYSE: LLY) stock has been a top performer thanks to runaway sales of its diabetes-turned-weight-management treatment. Despite nearly doubling over the past 12 months, Eli Lilly stock still has heaps of upside according to investment bank analysts who follow the century-old pharmaceutical giant. ...
motleyfoolusx:lly
By almost any measure, Eli Lilly (NYSE: LLY) stock has been a standout so far in 2024. Using a basic yardstick, the pharmaceutical sector giant's share price has climbed by over 33%, against the S&P 500 index's 5%. A mix of well-established commercialized drugs, a robust pipeline, and the company's recent ...
motleyfoolusx:lly
Image source: The Motley Fool. Eli Lilly (NYSE: LLY) Q1 2024 Earnings Call Apr 30, 2024, 10:00 a.m. ET Operator Continue reading
motleyfoolusx:lly
Shares of Eli Lilly and Company (NYSE: LLY) were jumping 6% higher as of 11:03 a.m. ET on Tuesday. The solid gain came after the big drugmaker announced its first-quarter 2024 results. Lilly reported Q1 revenue of $8.77 billion, up 26% year over year. This result came in a little below the average analyst's ...
motleyfoolusx:lly
Eli Lilly and Company (NYSE: LLY) reported first quarter 2024 earnings results today. Worldwide revenue was $8.77 billion, up 26% from the year-ago quarter, driven by increases of 16% in volume and 10% due to higher realized prices. Reported net income increased 67% to $2.24 billion, or $2.48 per share, ...
alphastreetusx:lly
Eli Lilly (NYSE: LLY), a juggernaut on the stock exchange with a $700 billion-plus market capitalization, has a lot going for it these days that should encourage investors. After all, its products are at the forefront of treating diabetes and weight loss. But one thing investors shouldn't expect are ...
motleyfoolusx:lly
The pharmaceutical business is a tricky one. Developing novel therapies costs hundreds of thousands of dollars, sometimes more. Many never make it to the market despite substantial sums invested by drugmakers. Many of those that do earn approval end up falling short of sales expectations. However, occasionally, ...
motleyfoolusx:lly
Nvidia has been an amazing stock to own over the past few years, generating incredible returns for investors. But the risk is that expectations may be too high for the stock, especially with respect to artificial intelligence (AI). And that means the stock could be vulnerable to a sell-off if reality ...
motleyfoolusx:llyusx:nvousx:unh
One of the hottest areas in the pharmaceutical space right now is weight loss. Glucagon-like peptide-1 (GLP-1) medications such as Ozempic, Wegovy, Rybelsus, Mounjaro, and Zepbound have become staples for treating diabetes and obesity. Eli Lilly (NYSE: LLY) is the developer of Mounjaro and Zepbound, ...
motleyfoolusx:lly
No risk, no reward. That's a fundamental part of investing. However, some stocks are less risky than others and still offer strong growth prospects. Three Motley Fool contributors think they've found relatively safe growth stocks you can buy and hold. Here's why they picked Eli Lilly (NYSE: LLY), Novo ...
motleyfoolusx:llyusx:vrtxusx:nvo
For both the biotech and pharmaceutical industries, what happens in the laboratory is critical to success (or failure, on the flip side). Some good news from a clinical trial conducted by Eli Lilly (NYSE: LLY) boosted the share price of the pharmaceutical giant (by 0.5%) on Wednesday, leaving several ...
motleyfoolusx:llyusx:ahcousx:rmd
Does a 100% return in less than seven years sound pretty good? Most investors would probably say so. But which stocks are good candidates to achieve such a gain? Three Motley Fool contributors think they've found magnificent stocks that could double or more by 2030. Here's why they picked CRISPR Therapeutics ...
motleyfoolusx:llyusx:vktxusx:crsp
Shares of Swiss pharmaceuticals giant Roche Holdings (OTC: RHHBY) stock popped 2.5% in early trading Thursday before giving back about half of its gains. Roche announced this morning that the U.S. Food and Drug Administration has awarded the "Breakthrough Device Designation" to its new Elecsys pTau217 ...
motleyfoolusx:lly
As two of the most-watched and fastest-growing big pharma companies, Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) already have upwardly mobile stock prices. And now, there's yet another piece of news that could presage even more growth over the long term. Let's explore this new development. Novo ...
motleyfoolusx:llyusx:nvo
The battle for leadership in the anti-obesity drug market is heating up. Eli Lilly (NYSE: LLY) and Novo Nordisk are the two undisputed frontrunners, but many other drugmakers are looking to challenge the status quo. Novo Nordisk's Wegovy, first approved in the U.S. in 2021, has been growing its sales ...
motleyfoolusx:lly
Investors were taking a healthy spoonful of the medicine that is Eli Lilly (NYSE: LLY) stock on Hump Day. They traded the company's shares up by nearly 2% on an analyst's recommendation upgrade. That figure was well above the scant (0.1%) gain posted by the S&P 500 index that day. The upgrade came from ...
motleyfoolusx:lly
Bear markets come and go, but history has taught investors time and time again that bull markets not only tend to outlast these periods, but eventually drive stocks higher than before the downturn hit. Both bull and bear markets can present opportunities for the long-term investor who is focusing on ...
motleyfoolusx:lly
The "it factor." Some stocks have it. Others don't. But when you find stocks with the "it factor," you'll want to load up on them. Three Motley Fool contributors believe they've identified three stocks that fit the bill. Here's why they think CRISPR Therapeutics (NASDAQ: CRSP), Eli Lilly (NYSE: LLY), ...
motleyfoolusx:llyusx:vrtxusx:crsp
Getting to a $1 trillion market cap is a huge achievement for a company, as only the best of the best can join that club. Not only do companies need to generate strong results, but investors also need to be optimistic about their future growth for their valuations to reach such highs. Two stocks that ...
motleyfoolusx:lly
Are stock splits back in style? About two years ago, a number of high-profile corporations made such moves after their shares rose to unwieldy levels. Now, Chipotle, one of the leading fast-casual restaurant chains, is on the verge of conducting a 50-for-1 stock split. It was arguably about time -- Chipotle ...
motleyfoolusx:regnusx:lly
